MEIP - MEIファ―マ (MEI Pharma Inc.) MEIファ―マ

 MEIPのチャート


 MEIPの企業情報

symbol MEIP
会社名 MEI Pharma Inc (MEIファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 MEIファーマ(MEI Pharma Inc.)(旧名:Marshall Edwards Inc)はがんの治療向けの薬物と治療の臨床開発に焦点を当てる癌治療に従事する会社である。同社の臨床薬候補のポートフォリオには、Pracinostat、ME-344及びME-401が含まれる。Pracinostatは、経口で利用可能なヒストンデアセチラーゼ(HDAC)阻害剤であり、急性骨髄性白血病(AML)と骨髄異形成症候群(MDS)などの血液疾患の治療に適応する。ME-344は、イソフラボン系ミトコンドリア阻害剤であり、急速に増殖する細胞中の末端呼吸鎖複合体のミトコンドリア成分を標的とする。ME-401は、血液癌細胞の増殖と生存に重要な役割を果たす分子標的であるホスファチジルイノシトイド3-キナーゼ(PI3K)デルタの経口阻害剤である。Pracinostatは、進行性血液悪性腫瘍と固形腫瘍適応症における複数の第I相と第II相臨床試験で試験される。  MEIファ―マは米国の腫瘍専門の医薬品メ―カ―。がん治療のための新薬の臨床開発に従事。主力製品候補の「Pracinostat」は、骨髄異形成症候群や急性骨髄性白血病などの進行性の血液疾患のために開発されている、経口投与可能なヒストンデアセチラ―ゼ阻害剤である。本社はサンディエゴ。   
本社所在地 3611 Valley Centre Drive Suite 500 San Diego CA 92130 USA
代表者氏名 Christine Anna White クリスティーナ・アンナ・ホワイト
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-792-6300
設立年月日 36861
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.meipharma.com
nasdaq_url https://www.nasdaq.com/symbol/meip
adr_tso
EBITDA EBITDA(百万ドル) -28.53300
終値(lastsale) 3.75
時価総額(marketcap) 266574015
時価総額 時価総額(百万ドル) 266.68290
売上高 売上高(百万ドル) 1.62200
企業価値(EV) 企業価値(EV)(百万ドル) 163.93990
当期純利益 当期純利益(百万ドル) -40.06800
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 MEI Pharma Inc revenues decreased 93% to $1.6M. Net loss totaled $40.1M vs. income of $2.7M. Revenues reflect License revenue decrease from $20.9M to $0K Research and development revenue decrease of 32% to $1.6M. Net loss reflects Research and development - Balancing val increase from $6.4M to $15.9M (expense) General and administrative - Balancing v increase of 8% to $7.7M (expense).

 MEIPのテクニカル分析


 MEIPのニュース

   MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update  2021/01/04 12:00:00 PR Newswire
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase ("PI3K")…
   MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIP  2020/12/19 03:50:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into MEI Pharma, Inc. (NasdaqGS: MEIP). From August 2017, the Company repeatedly touted the potency and effectiveness of its drug candidate, Pracinostat, in its Phase 2 trial. However, on July 2, 2020, the Company disclosed that it was discontinuing the Phase 3 trial of Pracinostat, due
   MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights  2020/11/10 21:05:00 PR Newswire
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September 30, 2020. "As we move through fiscal year 2021, we are well-positioned and…
   Myelodysplastic Syndromes (MDS) Market Overview, Outlook, Recent Trend By 2026 | Otsuka Holdings, Lupin, Johnson & Johnson, MEI Pharma, Mylan N.V.  2020/11/03 06:10:10 OpenPR
This Myelodysplastic Syndromes (MDS) Market research report is a great store to acquire current as well as upcoming technical and financial details of the industry for the precise forecast period. This market report also provides information about the brand awareness,
   Zacks: Brokerages Expect MEI Pharma Inc (NASDAQ:MEIP) Will Post Earnings of -$0.07 Per Share  2020/10/24 14:12:43 Transcript Daily
Analysts expect MEI Pharma Inc (NASDAQ:MEIP) to report earnings of ($0.07) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for MEI Pharma’s earnings. MEI Pharma reported earnings of ($0.17) per share in the same quarter last year, which indicates a positive year over year growth rate of […]
   MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights  2020/11/10 21:05:00 PR Newswire
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September 30, 2020. "As we move through fiscal year 2021, we are well-positioned and…
   Myelodysplastic Syndromes (MDS) Market Overview, Outlook, Recent Trend By 2026 | Otsuka Holdings, Lupin, Johnson & Johnson, MEI Pharma, Mylan N.V.  2020/11/03 06:10:10 OpenPR
This Myelodysplastic Syndromes (MDS) Market research report is a great store to acquire current as well as upcoming technical and financial details of the industry for the precise forecast period. This market report also provides information about the brand awareness,
   Zacks: Brokerages Expect MEI Pharma Inc (NASDAQ:MEIP) Will Post Earnings of -$0.07 Per Share  2020/10/24 14:12:43 Transcript Daily
Analysts expect MEI Pharma Inc (NASDAQ:MEIP) to report earnings of ($0.07) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for MEI Pharma’s earnings. MEI Pharma reported earnings of ($0.17) per share in the same quarter last year, which indicates a positive year over year growth rate of […]
   Lifesci Capital Reaffirms “Outperform” Rating for MEI Pharma (NASDAQ:MEIP)  2020/10/24 06:46:44 Transcript Daily
Lifesci Capital reissued their outperform rating on shares of MEI Pharma (NASDAQ:MEIP) in a report published on Wednesday, Zacks.com reports. Several other brokerages have also recently weighed in on MEIP. SunTrust Banks reduced their price target on MEI Pharma from $16.00 to $12.00 in a research report on Monday, July 6th. Ci Capital restated a […]
   Shareholder Alert: Robbins LLP Reminds Investors MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders  2020/10/23 22:22:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. One of MEI Pharma's drug candidates include Pracinostat, an oral histone de
   7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2020/10/02 13:47:13 NewMediaWire
Los Angeles, CA - (NewMediaWire) - October 2, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. (“MEI Pharma” or “the Company”) (NASDAQ: MEIP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2017 and July 1, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before October 9, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney.
   ROSEN, A LEADING LAW FIRM, Reminds MEI Pharma, Inc. Investors of Important October 9 Deadline in Securities Class Action - MEIP  2020/09/29 00:47:00 PR Newswire
NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the "Class Period"), of the important October 9, 2020 lead plaintiff…
   MEI Pharma (MEIP) Presents At H.C. Wainwright 22nd Annual Global Investment Conference - Slideshow (NASDAQ:MEIP)  2020/09/17 18:33:52 Seeking Alpha
The following slide deck was published by MEI Pharma, Inc. in conjunction with this event..
   MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing  2020/09/15 12:00:00 PR Newswire
SAN DIEGO, Sept. 15, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Brian T. Powl as senior vice president, marketing, a new role that will report to David…
   ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of Important October 9 Deadline in Securities Class Action - MEIP  2020/09/14 20:32:00 PR Newswire
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the "Class Period"), of the important October 9, 2020 lead plaintiff…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 MEIファ―マ MEIP MEI Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)